Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

M. McKean; M. Barve; D. Hong; A. Parikh; E. Rosen; J. Yang; R. Picard; J. Yi; L. Brail; D. Vecchio; T. Meniawy; T. John; J. Wang

doi:10.1016/S0959-8049(22)00890-5

Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

M. McKean, M. Barve, D. Hong, A. Parikh, E. Rosen, J. Yang, R. Picard, J. Yi, L. Brail, D. Vecchio, T. Meniawy, T. John, J. Wang

Investigational Cancer Therapeutics

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	S34
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)00890-5
State	Published - Oct 2022

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/S0959-8049(22)00890-5

Cite this

McKean, M., Barve, M., Hong, D., Parikh, A., Rosen, E., Yang, J., Picard, R., Yi, J., Brail, L., Vecchio, D., Meniawy, T., John, T., & Wang, J. (2022). Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors. European Journal of Cancer, 174, S34. https://doi.org/10.1016/S0959-8049(22)00890-5

McKean, M, Barve, M, Hong, D, Parikh, A, Rosen, E, Yang, J, Picard, R, Yi, J, Brail, L, Vecchio, D, Meniawy, T, John, T & Wang, J 2022, 'Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors', European Journal of Cancer, vol. 174, pp. S34. https://doi.org/10.1016/S0959-8049(22)00890-5

@article{9fcc8c737e6e42b7bc0c7b368a8678c2,

title = "Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors",

author = "M. McKean and M. Barve and D. Hong and A. Parikh and E. Rosen and J. Yang and R. Picard and J. Yi and L. Brail and D. Vecchio and T. Meniawy and T. John and J. Wang",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)00890-5",

language = "English (US)",

volume = "174",

pages = "S34",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Preliminary results from FLAGSHP-1

T2 - A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

AU - McKean, M.

AU - Barve, M.

AU - Hong, D.

AU - Parikh, A.

AU - Rosen, E.

AU - Yang, J.

AU - Picard, R.

AU - Yi, J.

AU - Brail, L.

AU - Vecchio, D.

AU - Meniawy, T.

AU - John, T.

AU - Wang, J.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140489633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140489633&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)00890-5

DO - 10.1016/S0959-8049(22)00890-5

M3 - Article

AN - SCOPUS:85140489633

SN - 0959-8049

VL - 174

SP - S34

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this